Table 1

Description of Study and Baseline Characteristics for Included Studies

Drug

Author Year

Study

Duration

(years)

Country/Region

Number of

Centres

Age (yrs)

Mean(SD)

Years

Menopause

Inclusion Criteria

Years Since

Menopause

Mean (SD)

BMD Hip

g/cm2

Mean (SD)

Prior

Vertebral

Fracture %


Alendronate

Ascott Evans 2003

1

International

18

67.3 (6.6)

3

11.5 (7.3)

nr

0


Alendronate

Black 1996

3

North America

11

71.0 (5.6)

2

NR (NR)

0.57 (0.07)

100


Alendronate

Cummings 1998

4

North America

11

67.6 (6.1)

2

NR (NR)

0.84 (0.13)

0


Alendronate

Greenspan 1998

2.5

North America

1

70.0 (4.6)

NR

NR (NR)

0.57 (0.11)

NR


Alendronate

Liberman 1995

3

International

NR

64.0 (7.0)

5

16.5 (NR)

0.71 (NR)

21


Alendronate

Pols 1999

1

International

153

62.8 (7.4)

3

15.9 (1.5)

0.72 (0.08)

NR


Denosumab

Cummings 2009

4

North America

11

67.7 (6.6)

2

NR (NR)

0.84 (0.13)

0


Etidronate

Lyritis 1997

4

Europe

1

72.0 (0.4)

NR

25.8 (1.7)

0.57 (NR)

100


Etidronate

Meunier 1997

4

Europe

1

52.7 (4.0)

0.5

2.4 91.8)

0.90 (NR)

NR


Etidronate

Montesorri 1997

3

Europe

2

62.5 (6.2)

1

14.9 (6.1)

0.67 (NR)

29


Etidronate

Pacifici 1988

2

U.S.A

1

61.0 (7.8)

NR

13.8 (9.5)

0.79 (0.26)

100


Etidronate

Pouilles 1997

2

Europe

7

53.8 (3.1)

0.5

2.6 (1.4)

0.96 (NR)

NR


Etidronate

Storm 1990

3

Europe

1

68.3 (7.3)

NR

21.6 (10.2)

0.25 (0.07)

100


Etidronate

Watts 1990

2

U.S.A

7

65.1 (13.0)

1

17.9 (16.5)

0.86 (NR)

100


Etidronate

Wimalawansa 1998

4

NR

NR

64.9 (7.8)

NR

15.1 (6.8)

0.83 (NR)

100


Ibandronate

Chesnut 2004

3

Europe, U.S.A

73

69.0 (11.0)

5

21 (20.8)

0.78 (NR)

93


Ibandronate

Ravn 2002

1

Europe

1

64.5 (5.9)

10

NR (NR)

0.87 (0.13)

28


Ibandronate

Adami 2004

1

Europe

NR

65.9 (4.5)

5

17.9 (4.0)

0.77 (0.09)

45


Ibandronate

Recker 2004

3

Europe

NR

67.0 (5.1)

5

NR (NR)

0.80 (0.11)

54


Raloxifene

Ettinger 1999

3

International

180

66.1 (6.9)

2

18.6 (7.9)

0.58 (NR)

38


Risedronate

Fogelman 2000

2

Europe

13

64.7 (7.2)

1

17.7 (9.4)

0.74 (0.08)

30


Risedronate

Harris 1999

3

North America

110

69.0 (7.3)

5

24.0 (9.9)

0.83 (0.16)

81


Risedronate

Hooper 2005

2

Australia

11

52.6 (3.3)

0.5

3.9 (5.6)

1.08 (0.12)

18.3


Risedronate

McClung 2001

3

International

183

78.0 (9.7)

NR

31.8 (19.3)

NR (NR)

42


Risedronate

Mortenson 1998

2

International

2

51.2 (3.8)

0.5

2.7 91.7)

0.94 (0.11)

NR


Risedronate

Reginster 2000

3

Europe, Australia

80

71.0 (7.0)

5

24.4 (8.5)

0.79 (0.15)

100


Strontium

Meunier 2004

3

Europe, International

72

69.3 (7.3)

5

43.7 (8.7)

0.68 (0.11)

100


Strontium

Reginster 2008

3.5

International

75

76.7 (5.0)

0

28.4 (7.4)

0.55 (NR)

33.5


Teriparatide

Neer 2001

2

International

99

69.0 (7.0)

5

21.0 (8.0)

0.82 (0.17)

100


Zoledronate

Black 2007

3

U.S.A, Europe

60

73 (5.4)

0

NR (NR)

0.65 (0.91)

36.7


NR: Not reported. BMD: Bone Mineral Density. SD: Standard deviation. U.S.A: United States of America

Hopkins et al. BMC Musculoskeletal Disorders 2011 12:209   doi:10.1186/1471-2474-12-209

Open Data